Cytochrome P450 Antagonist

20-SOLA is an orally active 20-HETE antagonist. 20-SOLA greatly ameliorates changes in blood pressure and renal injury associated with a Streptozotocin (STZ) (HY-13753)-diabetic mouse model. 20-SOLA facilitates the restoration of coronary collateral growth (CCG) after ischemic injury. 20-SOLA can be studied for research in cardiovascular diseases and diabetes.

20-HEDE (WIT 002) is an antagonist of 20-hydroxyeicosatetraenoic acid (20-HETE).

4-Chlorophenylacetic acid is an aromatase antagonist. 4-Chlorophenylacetic acid inhibits estrogen-induced breast tumorigenesis by blocking estrogen conversion. 4-Chlorophenylacetic acid also serves as the sole carbon and energy source for Pseudomonas sp. CBS3; it is degraded via dechlorination and aromatic ring cleavage pathways, and induces the synthesis of protocatechuate 2,3-dioxygenase. 4-Chlorophenylacetic acid can be applied to studies related to estrogen-induced breast tumors and bacterial degradation pathways.

4-Chlorophenylacetic acid (Standard) is the analytical standard of 4-Chlorophenylacetic acid (HY-W010062). This product is intended for research and analytical applications. 4-Chlorophenylacetic acid is an aromatase antagonist. 4-Chlorophenylacetic acid inhibits estrogen-induced breast tumorigenesis by blocking estrogen conversion. 4-Chlorophenylacetic acid also serves as the sole carbon and energy source for Pseudomonas sp. CBS3; it is degraded via dechlorination and aromatic ring cleavage pathways, and induces the synthesis of protocatechuate 2,3-dioxygenase. 4-Chlorophenylacetic acid can be applied to studies related to estrogen-induced breast tumors and bacterial degradation pathways.

Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT).